DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) major shareholder Jan Stahlberg bought 40,253 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were bought at an average cost of $7.89 per share, with a total value of $317,596.17. Following the completion of the transaction, the insider owned 8,752,643 shares in the company, valued at $69,058,353.27. The trade was a 0.46% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Jan Stahlberg also recently made the following trade(s):
- On Tuesday, November 25th, Jan Stahlberg purchased 73,099 shares of DiaMedica Therapeutics stock. The stock was bought at an average price of $8.57 per share, for a total transaction of $626,458.43.
- On Friday, November 21st, Jan Stahlberg purchased 208,872 shares of DiaMedica Therapeutics stock. The stock was bought at an average cost of $7.41 per share, with a total value of $1,547,741.52.
- On Thursday, November 20th, Jan Stahlberg acquired 128,426 shares of DiaMedica Therapeutics stock. The shares were bought at an average price of $7.41 per share, with a total value of $951,636.66.
- On Wednesday, November 19th, Jan Stahlberg acquired 240,352 shares of DiaMedica Therapeutics stock. The stock was bought at an average cost of $7.21 per share, for a total transaction of $1,732,937.92.
- On Tuesday, November 18th, Jan Stahlberg bought 182,882 shares of DiaMedica Therapeutics stock. The shares were purchased at an average cost of $6.75 per share, with a total value of $1,234,453.50.
- On Monday, November 17th, Jan Stahlberg purchased 187,393 shares of DiaMedica Therapeutics stock. The shares were purchased at an average price of $6.52 per share, with a total value of $1,221,802.36.
DiaMedica Therapeutics Stock Performance
Shares of NASDAQ DMAC opened at $8.76 on Tuesday. The company's 50 day moving average price is $7.15 and its 200-day moving average price is $5.73. DiaMedica Therapeutics, Inc. has a 52-week low of $3.19 and a 52-week high of $9.23. The company has a market capitalization of $456.22 million, a P/E ratio of -12.34 and a beta of 1.31.
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Analysts forecast that DiaMedica Therapeutics, Inc. will post -0.59 earnings per share for the current year.
Institutional Investors Weigh In On DiaMedica Therapeutics
Hedge funds have recently added to or reduced their stakes in the company. Cantor Fitzgerald L. P. bought a new stake in shares of DiaMedica Therapeutics during the third quarter valued at approximately $687,000. Private Capital Management LLC acquired a new stake in DiaMedica Therapeutics in the 3rd quarter valued at $344,000. Qube Research & Technologies Ltd bought a new stake in DiaMedica Therapeutics during the 3rd quarter valued at $272,000. Millennium Management LLC acquired a new position in DiaMedica Therapeutics during the third quarter worth $8,157,000. Finally, Citadel Advisors LLC bought a new position in shares of DiaMedica Therapeutics in the third quarter valued at $476,000. Institutional investors and hedge funds own 10.12% of the company's stock.
Analyst Ratings Changes
Several research analysts have recently weighed in on DMAC shares. Cantor Fitzgerald began coverage on DiaMedica Therapeutics in a research report on Friday, November 14th. They issued an "overweight" rating for the company. TD Cowen initiated coverage on DiaMedica Therapeutics in a report on Thursday, October 30th. They issued a "buy" rating for the company. Cowen started coverage on DiaMedica Therapeutics in a research note on Thursday, October 30th. They issued a "buy" rating on the stock. Wall Street Zen lowered shares of DiaMedica Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of DiaMedica Therapeutics in a research report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $12.33.
Get Our Latest Report on DiaMedica Therapeutics
About DiaMedica Therapeutics
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
